T. Rowe Price (TROW) Q1 2026 Earnings Transcript

T. Rowe Price reported Q1 adjusted EPS of $2.52, up 13% year over year, with average AUM of $1.78 trillion and adjusted net revenue above $1.8 billion, but firmwide net outflows remained $13.7 billion. Strength was concentrated in target date products ($4.9 billion of inflows), ETFs ($2.8 billion), and SMAs ($962 million), while equity and mutual fund outflows persisted and the effective fee rate fell to 38.4 bps. Management kept 2026 expense guidance at 3%-6% growth, raised the dividend for the 40th straight year to $1.30, and repurchased $340 million of stock.

Analysis

The core signal is not the headline outflow print, but the bifurcation in flow quality: lower-fee, sticky solution products are gaining share while legacy higher-fee equity/mutual fund assets keep bleeding. That mix is structurally negative for near-term revenue yield, but it also makes earnings more resilient than the market likely assumes because operating leverage is now coming from expense discipline rather than top-line growth. In other words, TROW is becoming a lower-growth, higher-conversion cash compounder, and the market may still be pricing it as if fee pressure will keep outrunning cost control.

The second-order winner is the alternatives platform, especially where distribution can cross-sell private credit into retirement, wealth, and insurance channels. If OHA’s fundraising momentum continues, the strategic value to TROW is less about immediate EPS contribution and more about defending relevance with advisors that are reallocating away from plain-vanilla mutual funds toward packaged solutions. The key competitive risk is that larger platform rivals can replicate the wrapper faster than they can replicate underwriting culture, which means product breadth may matter more than raw AUM growth over the next 12-18 months.

The market is also underestimating how much the current credit volatility helps a manager with dry powder and institutional credibility. Wider spreads and more client requests for dislocation capital create a near-term fundraising tailwind for OHA, but retail alternatives remain the swing factor because that channel is more sentiment-sensitive and could remain volatile if redemptions across the industry worsen. The main catalyst to re-rate the stock is not an immediate return to net inflows; it is evidence that ETF/SMA/alternatives can offset ongoing mutual fund attrition enough to stabilize fee rate and make buybacks meaningfully accretive.

Contrarian view: the stock is less a "broken growth story" than a transition story with optionality. Consensus is likely over-fixated on the headline outflow number and underweight the cumulative effect of product mix shift, expense reset, and capital return. The risk is that if equity outflows persist for another few quarters, the fee-rate drag could overwhelm operating savings and delay any multiple expansion.

Key Decisions for Investors

• Long TROW on a 6-12 month horizon as a quality/turnaround cash compounder; use weakness from any outflow-driven selloff to build, targeting rerating if net flows stabilize and ETF/SMA assets keep compounding.
• Pair trade: long TROW / short a higher-fee active mutual fund manager with weaker balance-sheet flexibility over the next 2 quarters; thesis is that fee compression hurts both, but TROW has better capital return capacity and product diversification.
• Buy TROW calls or call spreads 9-12 months out if the stock is trading near post-earnings lows; catalyst is a narrowing gap between cost growth and revenue yield plus continued buyback acceleration.
• Within alternatives, favor TROW over pure-play retail private-credit names for now; the institutional franchise reduces funding risk, but size the position smaller until retail redemption trends normalize.
• If the stock rallies sharply on enthusiasm for OHA, take partial profits into strength: the near-term multiple can overshoot before core equity flows actually inflect.